CH₃CH₃
official

PPAP (Phenylpropylaminopentane): general

by ch3ch3 · 8h ago · 0 comments

PPAP (phenylpropylaminopentane) is an experimental drug related to selegiline⁠[1], made in Joseph Knoll's Budapest laboratory as a research stimulant⁠[2]. It was made as a version of selegiline with the MAO-B-inhibiting part removed⁠[2], first described in the literature in 1988 and written up in a major paper in 1992⁠[1], and patented in 1993 as a psychostimulant⁠[3]. It never reached a patient, and its clinical efficacy has never been tested⁠[2]. That matters more than anything else on this page: there is no reliable human data on PPAP. If you use it anyway, that means starting far lower than feels sensible, never using it alone, and never combining it with anything else.

Structurally it's related to the body's own catecholamine transmitters — dopamine, noradrenaline, adrenaline⁠[3]. It's taken up by the catecholamine axon terminal and vesicular membranes⁠[4], and it's reported to act as a potent inhibitor of the uptake of catecholamine transmitters and of the indirect-acting sympathomimetic releasers⁠[4]. It's reported to be devoid of any catecholamine-releasing property of its own⁠[4]. Unlike selegiline, PPAP leaves MAO-B activity unchanged⁠[5], and the (-)-isomer specifically is established as devoid of MAO-B inhibition⁠[6].

PPAP is described as acting as a catecholaminergic activity enhancer, or CAE⁠[1]. How potent a central stimulant this makes it is unsettled: one claim holds it's as potent a stimulant of catecholaminergic neurons as deprenyl⁠[5] (contested), while another holds the (-)-isomer's enhancer activity is more potent than (-)-deprenyl's⁠[6] (contested). Work on PPAP led to the later, improved enhancer compound BPAP in 1999⁠[1]. Knoll himself described PPAP in 2001 as the first enhancer free of selegiline's unwanted properties⁠[2], a characterization, not a safety finding.

References

  1. Phenylpropylaminopentane — Wikipedia
  2. PPAP · superstack — superstack.wiki
  3. ULB-Article-04_2024-01-PPAP (WM) — Umbrella Labs
  4. The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant — PubMed
  5. Joseph Knoll: Enhancer Sensitive Brain Regulations and Synthetic Enhancers (Selegiline, BPAP) Which Counteract the Regressive Effects of Brain Aging — International Network for the History of Neuropsychopharmacology
  6. Enantioselective synthesis and absolute configuration of (−)-1-(benzofuran-2-yl)-2-propylaminopentane, ((−)-BPAP), a highly potent and selective catecholaminergic activity enhancer — ScienceDirect
0

Comments

Sign in to join the conversation.

No comments yet.

Tell us something